市場調査報告書：RNAi

Abstract

This Market Insight Report on RNAi covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions- United States, Europe , Asia-Pacific and Rest of World. The RNAi Tools/Products are further segmented into Design/Software (miRNA Target Scan, miRNA Analysis Software, and Design Software), Synthesis (Expression Vectors, Chemical, iRNA Isolation, Dicer/RNAseIII, and In Vitro), Delivery (Vector Based, Transfection Reagents, and Electroporation), Monitoring/Optimizing (Primers for RTqPCR, Controls, and miRNA Detection Tools), and Libraries (Human, Mouse, and Rat). Application by Research (Functional Genomics, Metabolism, and Protein Chemistry), Therapeutics (Oncology, Neurology, Ophthalmology, and Virology) and Drug Development (Target Identification, Target Validation, and Drug Mechanism) are also analyzed. Business profiles of 42 major companies are discussed in the report.

The report serves as a guide to global RNAi industry covering 213 companies that are engaged in RNAi synthesis, R&D, therapeutics, test kits, tools and services. Major Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report. Projections and estimates are graphically illustrated by geographic , region with exclusive graphical representations provided for 384 exhibits.

I. SCOPE AND METHODOLOGY

II. REPORT SYNOPSIS

1.Introduction
- Introduction to RNAi
- RNAi- Nature' s Way of Silencing Gene
- Definition
- Summary
- History of RNAi
  - Segmentation of RNAi
  - Exhibit 1: Segmentation of Global RNAi Market by Application (Research, Therapeutics, Drug Development and Other) and Tools/Products (Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other)
  - Exhibit 2: Segmentation by Application (Research, Therapeutics, Drug Development & Other)
  - Exhibit 3: Segmentation by Tools/Products (Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other)
- Facts About RNAi
- Relation between siRNA Length and siRNA Function
- Functional Significance of siRNA Length
- Is siRNA Length Influential of siRNA Function?
- The Use of RNAi in Mammalian System
2.Global Market Analysis
- Exhibit 4: RNAi (2005-2012) -Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
Analysis by Segmentation
- Application
  - Exhibit 5: RNAi (2005-2012)-Global Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 6: RNAi (2006, 2009 and 2012) -Percentage Breakdown of Global Market Value by Application for Research, Therapeutics, Drug Development and Other
- Tools/Products
  - Exhibit 7: RNAi (2005-2012) - Global Market Analysis (Current & Future) by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries, and Other in US$ Million (Graphical Representation Included)
  - Exhibit 8: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
Application Analysis by Geographic Region
- Research
  - Exhibit 9: RNAi in Research (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 10: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and, Rest of World
- Therapeutics
  - Exhibit 11: RNAi in Therapeutics (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 12: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World
- Drug Development
  - Exhibit 13: RNAi in Drug Development (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 14: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World
- Other
  - Exhibit 15: RNAi in Other Application (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 16: RNAi in Other Application (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World
- Tools/Products Analysis by Geographic Region
- Design/Software
  - Exhibit 17: RNAi Design/Software Tools/Products (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 18: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World
- Synthesis
  - Exhibit 19: RNAi Synthesis Tools/Products (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 20: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World
- Delivery
  - Exhibit 21: RNAi Delivery Tools/Products (2005-2012) - Global Market Analysis (Current and Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 22: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World
- Monitoring/Optimizing
  - Exhibit 23: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 24: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World
- Libraries
  - Exhibit 25: RNAi Libraries (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 26: RNAi Libraries (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World
- Other
  - Exhibit 27: RNAi - Other Tools/Products (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 28: RNAi - Other Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, and Rest of World
  - Exhibit 29: List of Major Global Companies
3. Regional Market Analysis
- United States
  - Exhibit 30: RNAi (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Major Companies in the US
  - Allele Biotechnology and Pharmaceuticals, Inc.
  - Alnylam Pharmaceuticals, Inc.
  - Ambion, Inc.
  - Applied Biosystems Group
  - Asuragen, Inc.
  - Avalon Pharmaceuticals, Inc.
  - B-Bridge International, Inc.
  - Clontech Laboratories, Inc.
  - Calando Pharmaceuticals, Inc.
  - CombiMatrix Corporation
  - CytRx Corporation
  - RXi Pharmaceuticals Corporation
  - Dharmacon, Inc.
  - Galenea Corporation
  - Imgenex Corporation
  - Intradigm Corporation
  - Intronn, Inc.
  - Invitrogen Corporation
  - InvivoGen
  - Lentigen Corporation
  - Merck & Co. , Inc.
  - Mirus Bio Corporation
  - Nastech Pharmaceutical Company, Inc.
  - Nucleonics, Inc.
  - Open Biosystems, Inc.
  - Opko Health, Inc.
  - Panomics, Inc.
  - Promega Corporation
  - SomaGenics, Inc.
  - Sigma-Aldrich Corporation
  - Targeted Genetics Corporation
- Analysis by Application
  - Research
  - Exhibit 31: RNAi in Research (2005-2012) - - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Therapeutics
  - Exhibit 32: RNAi in Therapeutics (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Drug Development
  - Exhibit 33: RNAi in Drug Development (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Other
  - Exhibit 34: RNAi in Other Application (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Tools/Products
  - Design/Software
  - Exhibit 35: RNAi Design/Software Tools/Products (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Synthesis
  - Exhibit 36: RNAi Synthesis Tools/Products (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Delivery
  - Exhibit 37: RNAi Delivery Tools/Products (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Monitoring/Optimizing
  - Exhibit 38: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Libraries
  - Exhibit 39: RNAi Libraries (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Other
  - Exhibit 40: RNAi Other Tools/Products (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Europe
  - Exhibit 41: RNAi (2005-2012) - European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Major Companies in Europe
  - Actigenics SA (France)
  - Cenix Bioscience GmbH (Germany)
  - deVGen NV (Belgium)
  - Qiagen N V
  - RNAx GmbH (Germany)
  - Santaris Pharma A/S (Denmark)
  - Silence Therapeutics plc (UK)
- Application Analysis by Geographic Region
  - Research
  - Exhibit 42: RNAi in Research (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 43: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe
  - Therapeutics
  - Exhibit 44: RNAi in Therapeutics (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 45: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
  - Drug Development
  - Exhibit 46: RNAi in Drug Development (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 47: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
  - Other
  - Exhibit 48: RNAi in Other Application (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 49: RNAi in Other Application (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Tools/Products Analysis by Geographic Region
  - Design/Software
  - Exhibit 50: RNAi Design/Software Tools/Products (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 51: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe
  - Synthesis
  - Exhibit 52: RNAi Synthesis Tools/Products (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 53: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe(Graphical Representation Included)Delivery
  - Exhibit 54: RNAi Delivery Tools/Products (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 55: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe
  - Monitoring/Optimizing
  - Exhibit 56: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 57: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, UK, Belgium, France, and Rest of Europe (Graphical Representation Included)
  - Libraries
  - Exhibit 58: RNAi Libraries (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 59: RNAi Libraries (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
  - Other
  - Exhibit 60: RNAi Other Tools/Products (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 61: RNAi Other Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
  - Asia-Pacific
  - Exhibit 62: RNAi (2005-2012) - Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Major Companies in Asia-Pacific
  - alphaGEN Co. , Ltd
  - Antisense Therapeutics Limited (Australia)
  - Benitec Ltd. (Australia)
  - CytoPathfinder, Inc. (Japan)
- Application Analysis by Geographic Region
  - Research
  - Exhibit 63: RNAi in Research (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 64: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific
  - Therapeutics
  - Exhibit 65: RNAi in Therapeutics (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 66: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific
  - Drug Development
  - Exhibit 67: RNAi in Drug Development (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 68: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Other
  - Exhibit 69: RNAi in Other Application (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 70: RNAi in Other Application (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Tools/Products Analysis by Geographic Region
  - Design/Software
  - Exhibit 71: RNAi Design/Software Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 72: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Synthesis
  - Exhibit 73: RNAi Synthesis Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 74: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Delivery
  - Exhibit 75: RNAi Delivery Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 76: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Monitoring/Optimizing
  - Exhibit 77: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 78: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Libraries
  - Exhibit 79: RNAi Libraries (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 80: RNAi Libraries (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Other
  - Exhibit 81: RNAi Other Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 82: RNAi Other Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
  - Rest of World
  - Exhibit 83: RNAi (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Research
  - Exhibit 84: RNAi in Research (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Therapeutics
  - Exhibit 85: RNAi in Therapeutics (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Drug Development
  - Exhibit 86: RNAi in Drug Development (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Other
  - Exhibit 87: RNAi in Other Application (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Tools/Products
  - Design/Software
  - Exhibit 88: RNAi Design/Software Tools/Products (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Synthesis
  - Exhibit 89: RNAi Synthesis Tools/Products (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Delivery
  - Exhibit 90: RNAi Delivery Tools/Products (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Monitoring/Optimizing
  - Exhibit 91: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Libraries
  - Exhibit 92: RNAi Libraries (2005-2012) - Rest of world Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Other
  - Exhibit 93: RNAi Other Tools/Products (2005-2012) - Rest of world Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

III. PRODUCT/TECHNOLOGY RESEARCH

1. Introduction
- Introduction to RNA
  - Discovery of RNA interference
  - Revelation of RNAi Mechanism
  - System of RNAi
  - Molecular Structure of RNA
  - Synthesis of RNA
  - Varieties of RNA and their Biological Roles
  - Messenger RNA or mRNA in short
  - Transfer RNA tRNA in short
  - Ribosomal RNA or rRNA in short
  - Non-coding RNA or "RNA genes"
  - Double-stranded RNA or dsRNA in short
  - Translation RNA
  - Definition and Overview
  - Vital Methods Involved in the Translation Mechanism
  - Initiation Phase
  - Elongation Phase
  - Termination
  - Eukaryotic Translation
  - The Process of Initiation
    - The Cap-Dependent Initiation
    - The Cap-Independent Initiation
  - Understanding the RNAissance
  - RNAi Approaches in Production of Small RNAs for Host Gene Management
  - RNAi Functions
  - RNAi Growth Trends Global Markets
    - Exhibit 94: Global RNAi Market: Geographic Regions (Rest of World, Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  - Discovery of RNA Interference
  - Mechanism of Action
  - Mechanism of RNA Interference
  - Double-Stranded RNA Triggers RNAi
  - Processing of dsRNA Triggers and Assembly with RISC
  - RISC Assembly
  - Effector/Silencing Step
  - RNAi-Applications & Experiments
  - RNAi in Plants
  - History of Silencing Phenomena
  - The Blue Rose A Result of Plant Gene Replacement
  - Protein Complexes involved in the Development of Plants
  - In Plant Biotechnology
  - RNA interference and Antisense
  - RNAi Knock-Down Mice: The New Technology for Post-Genomic Functional Genetics
  - The Development of RNAi Technology in Vivo
  - RNAi Technology in Disease Models
  - Introduction
  - RNA interference in Therapeutic Applications
  - Importance of RNAi
  - RNAi Protects Against Viral Infections
  - RNAi Maintains Genome Stability by Silencing the Mobile Elements
    - Mechanisms Similar to RNAi Process Inhibit the Protein Synthesis and Control the Development of Organisms
    - RNAi like Mechanisms Suppress Transcription and Condense Chromatin
    - RNAi May be the New Tool for Gene repression
    - RNAi Might Prove Useful in Future Gene Therapy
    - Applications of RNAi
    - Therapeutics
- Development of RNAi based Therapies
  - Non Therapeutics
  - Other RNAi Applications
  - RNA Interference Mode of Action
  - RNA Polymerase Involved in PTGS has Two Different Kinds of Action
  - New Method of Epigenetic Gene Silencing Involving RNA and Polycomb Group Proteins
- Gene Silencing A Tool to Inactivate Gene of our Choice
  - About Gene Silencing
  - Brief History of Gene Silencing Processes
  - Exhibit 95: A Comparative Analysis of Gene Silencing Techniques by Strategy, Type of Agent, and Outcome
- Transcriptional and Post Transcriptional Gene Silencing
- Post-Transcriptional Gene Silencing and RNAi Mechanism
- Other Gene Silencing Methods through RNAi
- Schematic of a Typical siRNA Expression Vector
- Long Term Silencing of GFP with pSilencerTM 2 1U6 Hygro
- Gene Silencing Induced by siRNA Expression Plasmids
- Silencing of Gene Expression by PCR-based siRNA Expression Cassettes
- RNA-Protein Interactions and Translation Repression
2. RNAi Applications
- Growth Trends Global RNAi Application Market
  - Exhibit 96: Global RNAi Market: Major Applications (Other, Therapeutics, Research and Drug Development) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Research
- Growth Trends Global Market RNAi in Research
  - Exhibit 97: Global RNAi Market in Research: Geographic Regions (Rest of World, Asia-Pacific, United States, and Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Functional Genomics
- Metabolic Pathways
- Protein Chemistry
- Therapeutics
- Growth Trends Global Market for RNAi in Therapeutics
  - Exhibit 98: Global Market for RNAi in Therapeutics: Geographic Regions (Asia-Pacific, Rest of World, Europe, and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Therapeutic Approaches based on RNA
- Challenges for RNA based Drugs
- Delivery, the Most Urgent Objective
- Drug Development
- Growth Trends Global Market for RNAi in Drug Development
  - Exhibit 99: Global Market for RNAi in Drug Development: Geographic Regions (Asia-Pacific, Rest of World, Europe, and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
3. RNAi Tools/Products
- Growth Trends Global RNAi Tools/Products
  - Exhibit 100: Global Market for RNAi: Tools/Products (Monitoring/Optimizing, Libraries, Synthesis, Delivery, Other, and Design/Software) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Design/Software
- Growth Trends Global Market for RNAi Design/Software
  - Exhibit 101: Global Market for Design/Software: Geographic Regions (United States, Europe, Asia-Pacific and Rest of World) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- RNAi Mediated with siRNAs
- Synthesis
- Growth Trends Global Market for RNAi Synthesis
  - Exhibit 102: Global Synthesis Market for RNAi : Geographic Regions (Rest of World, Asia-Pacific, Europe, and United States) Ranked by Projected CAGR - for 2005 through 2012 (Graphical Representation Included)
- Delivery
- Growth Trends Global Market for RNAi Delivery
  - Exhibit 103: Global Market for RNAi DeliveryTools/Products : Geographic Regions (Rest of World, Asia-Pacific, Europe, and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Key Techniques Used in Drug Delivery
- Electroporation
- Vector Based
- Transfection Reagents
- Monitoring/Optimizing
- Growth Trends Global Market for RNAi Monitoring/Optimizing
- Exhibit 104: Global Market for RNAi Monitoring/Optimizing: Geographic Regions (Rest of World, Asia-Pacific, Europe, and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Control Experiments
- Establishing Gene Knockdown
- Libraries
- Growth Trends Global Market for RNAi Libraries
  - Exhibit 105: Global Market for RNAi Libraries: Geographic Regions (Asia-Pacific, Rest of World, Europe and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  - Other
- Growth Trends Global Market for Other RNAi Tool/Products
  - Exhibit 106: Global Market for Other RNAiTools/Products: Geographic Regions (Asia-Pacific, Rest of World, Europe and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
4. Product Trends
- Screening Assays
- RNAi and Nanoproteins
- Importance of Targeting Tumor Cells and Nanotechnology' s Contribution
- Application of RNAi in Drug Manufacture and Benefits Attributed to its Use
- The Phenomenon of Gene Suppression or Gene Knockdown
- Various Applications of RNAi
- Application of RNAi Products as Potential Drug Candidates
- Use of RNAi Technology in Treatment of Various Blood Disorders
- Prominent Breakthrough in the Field of Cancer Research
- Use of RNAi in Healing Bacterial and Viral Disorders
- Application of RNAi in Treatment of HIV Cases
- Benefits Attributed to the Use of RNAi Technology In Hepatitis Disorders
- Application of RNAi in Treatment of Cardiovascular and Cerebral Vascular Disorders
- Application of RNAi Technology in Healing Neurodegenerative Disorders
- miRNA Varieties: Antiproliferative and Proapoptotic
- Prevention of Malaria by Transformation of Mosquito by RNAi
- The Application of RNAi in the Treatment of Metabolism Related Disorders
- Gene Therapy for Sickle Cell Disease
- Application of RNAi in the Field of Medicine
- Some Potential Applications of RNAi to Human Diseases
  - Hepatitis B Virus
  - Respiratory Syncytial Virus
  - Herpes Simplex Virus
  - Neurodegenerative Diseases
  - Cancers
- Clinical Trial Preparation
- The Vision and Future Prospects of The Research
- Achievements of RNAi Products
- Dark Areas and Hurdles in the Research
  - Support of Major Pharmaceutical Companies-A key to Success
  - Exhibit 107: Major Pharma Companies The RNAi Connection
  - Advantages of RNAi Over Others
- RNAi in Research
  - RNAi Revolutionizes Research
  - An Array of Benefits
  - In Vivo Gene Silencing
  - Vitravene The Only Antisense Drug Approved
  - RNAi - A Natural Alternative
  - Antisense DNA or RNA
  - Delivery, Delivery, Delivery
  - Looking Ahead to the Clinic
- RNAi in Drug Discovery & Therapeutics
  - Combining Tools and Technologies to Improve Delivery and Efficacy of Key Compounds
  - Delivery and Efficacy
  - Lentiviral Delivery
  - Reducing Off-target Effects
  - Validating Knockdown
  - MicroRNA Mimics
  - RNAi Goes Genomic
- SPOT-RNAi Cell Arrays
- Methods for Incorporating RNAi in the Process of Drug Discovery
  - Sequence Determination
  - dsRNA Production
  - Screening and Optimization
  - Validation
  - Delivery
- Sequence Design Parameters
  - Design Parameters
  - Filter Selection Criteria
- Parallel dsRNA Production
  - Screening Assays
- RNAi and the Human Genome
  - Experimentation in Ribonucleic Acid interference
- Built-in RNAi Machinery for the Development of Plants
- Post-Transcriptional Gene Silencing in Drosophila Cells Mediated by RNA-Directed Nuclease
- Influence of Chromosome Organization and Chromatin Modification of Genome Function and Evolution
- Effective Genetic Interference by Double Stranded RNA in Caenorhabditis Elegans
- Structural Function for Double-Stranded RNA processing by Dicer
- The Role of Bidentate Ribonuclease in Initiating RNA Interference
- Cleavage of mRNA by Double-Stranded RNA at Intervals of 21 and 23 Nucleotides
- The Preferential Binding of Long Double-Stranded RNAs by RDE-4 and the Subsequent Dimerization that is Essential for its Cleavage to siRNAs
- A New Link between the Initiation and Effector Stages of the RNAi Pathway in Drosophila
- Two Separate Populations of Primary and Secondary Effectors are Present During RNAi in Caenorhabditis Elegans
- Unprimed RNA Synthesis Result in Secondary siRNAs which then Form a Discrete Class
- The Individual Roles of the Argonaute Proteins in Small RNA-Directed RNA Cleavage Pathways
- The Role of Dicer-1 and Dicer-2 are different in the siRNA/miRNA Silencing Pathways of Drosophila
- High-Throughput RNAi Screening In Vitro: From Cell Lines to Primary Cells
- The Advantages and Disadvantages of the Interference Process in Mammals
- Introduction to Nucleofection and Application of RNAi in Gene Silencing
  - Effective Non-Viral Delivery
  - Available Optimized Protocols
  - 96-Well Shuttle
  - The Impact of Non Reagent-based Transfection
- Various Problem Areas of RNAi
  - RNA Interference: Problem Areas and Potential Applications for Treatment of Human diseases
  - Toxicities Owing to Competition with Cellular miRNAs
  - Off-Target Effects Caused Due to Seed Sequence
  - Triggering and Circumventing Interferon Responses
  - Problems to be Overcome in Gene Therapy Involving RNAi “Knock-down” Mice as In Vivo Model
- RNAi Enhances Drug Development
- RNAi Drug Candidates
- Benefits of RNAi-based Therapies
  - Using the RNAi Process to Develop New Cancer Drugs
- The Role of RNA Interference in Treating Disorders of the Central Nervous System
- Delivering on Promise of RNAi Therapeutics
- RNAi and Influenza
- The Future of RNA Interference
- Major Challenges Governing the Use of RNAi as a Therapy
  - siRNA: Considered Future of In Vivo Mammalian Gene Research
  - Critical Factors that Aid a Successful RNAi
  - A Strong siRNA Design
  - How to Choose a Model Cell System
  - Combining Optimized Parameters Helps in the Discovery of New Drugs

IV. MARKET DYNAMICS

1. Market Overview
- RNAi A Breakthrough in Molecular Biology
  - Global Market Analysis
  - Exhibit 108: RNAi (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 109: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
  - Joint Venture Between Ambion and Cenix Bioscience Offers First Human Genome-Wide siRNA Library
2. Market Trends
- RNAi An Emerging Class of Drugs in Pharmaceuticals
  - Biotech/Pharma Industries' Interest in RNAi
  - RNAi' s Functionality
  - Sourcing and Market Potential
  - Marketing Strategy
  - Economic Possibilities
  - The Mission Ahead for RNAi
  - Biotech Companies Realize to Gain Billions of Dollars by Applying RNAi Technology
- RNAi: Focus on Modeling Cellular Systems
  - Introduction
  - Initial Stages of Mammalian RNAi Screening
  - Development of Signaling Pathways Using a Mammalian RNAi Screen
  - Identification of Components in a Biological Process: RNA interference
  - Component Discovery
  - Reporter Assays and High-Content Image-based Screening
    - Well-Based Arrayed Screening
    - Pooled Screening
    - Cell Microarrays
  - Component Validation and Classification
  - Classification
  - Systems Analysis
- An Outlook on Binary Genetic Interactions with RNAi
- Hypothetical RNAi Screening for Cell-Growth Regulators
- Prospects of Knockdown Technology
- RNA interference (RNAi)
  - Introduction
  - Redefinition of RNA
  - Knockdown of Genes
  - RNAi on a Large Scale
  - RNAi: Beyond Machinery
  - Silencing Diseases
  - Principle Behind RNAi
  - Delivery
  - Area of Concern
3. Major Companies in RNAi Industry
- Actigenics SA (France)
- Allele Biothechnology and Pharmaceuticals, Inc. (USA)
- alphaGEN Co. , Ltd.
- Alnylam Pharmaceuticals, Inc. (USA)
- Ambion, Inc. (USA)
- Antisense Therapeutics Limited (Australia)
- Applied Biosystems Group (USA)
- Asuragen, Inc. (USA)
- Avalon Pharmaceuticals, Inc. (USA)
- Benitec Ltd. (Australia)
- B-Bridge International, Inc.(USA)
- Clontech Laboratories, Inc. (USA)
- Calando Pharmaceuticals, Inc. (USA)
- Cenix Bioscience GmbH (Germany)
- CombiMatrix Corporation (USA)
- CytoPathfinder, Inc. (Japan)
- CytRx Corporation (USA)
- RXi Pharmaceuticals Corporation (USA)
- deVGen NV (Belgium)
- Dharmacon, Inc. (USA)
- Galenea Corporation (USA)
- Imgenex Corporation (USA)
- Intradigm Corporation (USA)
- Intronn, Inc. (USA)
- Invitrogen Corporation (USA)
- InvivoGen (USA)
- Lentigen Corporation (USA)
- Merck & Co. , Inc
- Mirus Bio Corporation (USA)
- Nastech Pharmaceutical Company, Inc. (USA)
- Nucleonics, Inc. (USA)
- Open Biosystems, Inc. (USA)
- Opko Health, Inc. (USA)
- Panomics, Inc. (USA)
- Promega Corporation (USA)
- Qiagen N. V.
- RNAx GmbH (Germany)
- SomaGenics, Inc. (USA)
- Santaris Pharma A/S (Denmark)
- Sigma-Aldrich Corporation (USA)
- Silence Therapeutics plc (UK)
- Targeted Genetics Corporation (USA)
4. Major Activities in RNAi Industry
- Nastech Pharmaceutical Allocates its RNA-based Intellectual Property to its Subsidiary
- RXi Pharmaceuticals Acquires Exclusive Rights to RNAi Sequences to Genes
- Columbia University Medical Center and Rosetta Genomics in Development Collaboration
- Asuragen Offers Newly Developed microRNA Services
- Invitrogen Corp. and RXi Pharmaceuticals in Collaboration Agreement for Enhancement of RNAi Technology
- Exiqon' s Locked Nucleic Acids Licensed to Applied Biosystems
- New Series of siRNA Developed by Applied Biosystems
- Thermo Fisher Scientific and Lentigen Collaboration for Technology Development
- Universite de Montreal to Study RNAi through Collaboration with Sigma-Aldrich
- Isis and Alnylam Join Hands to Establish Regulus Therapeutics
- RNAi Center Funding in Massachusetts
- Silence Therapeutics Enters into Partnership with AstraZeneca
- RXi Pharma Signs License Agreement with Cold Spring Harbor Laboratory
- Two-Year Agreement between Mirus Bio and Pfizer for Evaluation of RNAi Delivery Technology
- RXi Pharma Receives RNAi Assets from Parent Company
- Applied Biosystems Launches the StepOne Real-Time PCR System
- Nastech Acquires Exclusive Rights to RNAi Intellectual Property and Technology
- Artemis Enters into Deal with Merck for Production of RNAi Mouse Models
- Senetek Enters into Agreement with Poland' s IBCPAS for Treating Brain Tumors
- Merck Buys Entire Stake in Sirna Therapeutics
- Joint Effort to make a New Facility for Proteomics Profiling and Drug Effects in Human Cells
- Framework Agreement signed between Cenix BioScience and Merck KGaA
- Invitrogen Launches Advanced Transfection Reagents
- Calando Picks Agilent for siRNA production
- Alnylam Receives Biodefense Contract worth US$ 23 million from Government Agency
- Bio-Rad Enters into Alliance with Integrated DNA Technologies for Developing RNAi
- Dharmacon Associates with Amaxa for Improved Delivery of siRNA into Complex Cell Types
- QIAGEN Enters into Alliance with CytoPathfinder for Developing Novel Equipment for High-Throughput RNAi Screening
- Sirna Signs an Agreement with GSK for Developing RNAi based Drugs for Respiratory Disease Treatment
- Applied Biosystems Acquires Complete Stake in the Ambion' s Research Products Division
- Nastech Acquires Galenea along with Galenea' s IP and Technology Rights
- Ambion Enters into Alliance with GE Healthcare for Reinforcing the study on Micro-RNA Microarray
- Non-Exclusive License Agreement Signed Between Alnylam Pharma and Eurogentec
- Ambion Furnishes Cepheid with Licenses of Armored RNA
- Ambion Extends Partnership with Wyeth for the Development and Supply of RNA
5. Major Product Innovations/Launches in RNAi Industry
- Qiagen Launches RNA Purification Kit
- RXi Pharmaceuticals Granted Australian Patent Application License
- RXi Pharmaceuticals Signs License Agreement with TriLink Biotechnologies for RNA Chemistry Technologies
- Sigma-Aldrich Introduces LentiExpress™ Technology for High-Throughput RNAi Screening
- Rosetta Genomics is Issued a Second Patent for MicroRNAs
- Rosetta Genomics Signs Collaboration Agreement with Ben Gurion University
- US Government Signs $38 6 Million Contract with Alnylam
- Open Biosystems Launches New shRNAmir Library for RNA Interference
- Quark Pharmaceuticals Presents Positive Results in Pre-Clinical Studies of Systemic RNAi Compound in ARF
- Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations to Treat Neurodegenerative Diseases
- Oligo PRO™ 24HT System for the Parallel Analysis of Oligonucleotide and RNAi Duplex Purity
- Mirus Bio Discovers New Breakthrough Technology for RNAi Therapeutics
- Kylin Therapeutics Signs License Agreement with Purdue University for RNAi Delivery Technology
- Partnership Between Intradigm and Agilent to Develop RNA Interference Oncology Therapeutic
- Alnylam Achieves Important Milestone in Collaborative Agreement
- Launch of New RNAi Services Laboratory to Continue Research in Drug Discovery and Development
- Alnylam Initiates New Research Program on RNAi Therapeutics
- Alnylam Announces Advancement of New RNAi Therapeutic Development Program
- Alnylam Grants License to Bio-Rad for Kreutzer-Limmer Patents in the RNAi Research Products Market
- Luminex and Exiqon Jointly Produce New microRNAs Product Line
- Mirus Bio Granted Broad RNAi Patent Using its Proprietary Hydrodynamic Intravascular Injection
- Invitrogen Launches Advanced Transfection Reagents
- Exiqon Establishes Sales Headquarters in the US
- Mirus Bio Announces New Tool for Gene Function Analysis
- Alnylam Grants Quark License to Develop and Commercialize RNAi Therapeutic Products
- Exiqon Signs License Agreement with Max Planck Society for Diagnostic Use of Micro-RNAs
- Abbott and Dharmacon Collaborate to Develop siRNA-Based Therapeutics
- Acuity signs a pact with ZaBeCor for developing anti-inflammatory siRNA
- Invitrogen Signs Agreement with genOway
- Invitrogen Launches Stealth™ RNAi Human Kinase Collection
- Novartis joins hands with Alnylam for RNAi Therapeutics Innovation
- SB introduces Genome-Wide Human and Mouse siRNA Libraries
Analysis by Application
- Exhibit 110: RNAi (2005-2012) - Global Market Analysis (Current & Future) by Application Area for Research, Therapeutics, Drug Development, and Other in US$ Million (Graphical Representation Included)
- Exhibit 111: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Application Area for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
Application Analysis by Research
- Exhibit 112: RNAi in Research (2005-2012) - Global Market Analysis (Current & Future) - by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 113: RNAi in Research (2006, 2009 and 2012)- Percentage Breakdown of Global Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
Application Analysis by Therapeutics
- Exhibit 114: RNAi in Therapeutics (2005-2012) - Global Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 115: RNAi in Therapeutics (2006, 2009 and 2012)- Percentage Breakdown of Global Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
Application Analysis by Drug Development
- Exhibit 116: RNAi in Drug Development (2005-2012)- Global Market Analysis (Current and Future) by bApplication for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 117: RNAi in Drug Development (2006, 2009 and 2012)- Percentage Breakdown of Global Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other (Graphical Representation Included)
Analysis by Tools/Products
- Exhibit 118: RNAi (2005-2012) - Global Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 119: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing , Libraries and Other (Graphical Representation Included)
Tools/Products Analysis by Design/Software
- Exhibit 120: RNAi Design/Software Tools/Products (2005-2012) - Global Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 121: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other (Graphical Representation Included)
Tools/Products Analysis by Synthesis
- Exhibit 122: RNAi Synthesis Tools/Products (2005-2012)- Global Market Analysis (Current and Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 123: RNAi Synthesis Tools/Products (2006, 2009 and 2012)-Percentage Breakdown of Global Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
Tools/Products Analysis by Delivery
- Exhibit 124: RNAi Delivery Tools/Products (2005-2012) - Global Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 125: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value for Vector Based, Transfection Reagents, Electroporation and Other
Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 126: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Global Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 127: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other (Graphical Representation Included)
Tools/Products Analysis by Libraries
- Exhibit 128: RNAi Libraries Tools/Products (2005-2012) - Global Market Analysis (Current and Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
- Exhibit 129: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
6. Regional Market Analysis
- A. The United States
  - Market Analysis
  - Exhibit 130: RNAi (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Exhibit 131: List of Major Companies in the US
  - Analysis by Application
  - Exhibit 132: RNAi Applications (2005-2012) - United States Market Analysis (Current and Future) for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 133: RNAi Applications (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 134: RNAi in Research (2005-2012)- United States Market Analysis (Current & Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 135: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 136: RNAi in Therapeutics (2005-2012)- United States Market Analysis (Current & Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 137: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
  - Application Analysis by Drug Development
  - Exhibit 138: RNAi in Drug Development (2005-2012) - United States Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 139: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 140: RNAi Tools/Products (2005-2012) - United States Market Analysis (Current & Future) for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 141: RNAi Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 142: RNAi Design/Software Tools/Products (2005-2012) - United States Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 143: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 144: RNAi Synthesis Tools/Products (2005-2012) - United States Market Analysis (Current & Future) for Expression Vectors, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 145: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 146: RNAi Delivery Tools/Products (2005-2012) - United States Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 147: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 148: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - United States Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 149: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 150: RNAi Libraries Tools/Products (2005-2012) - United States Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 151: RNAi Libraries Tools/Products (2006, 2009 and 2012) Breakdown of United States Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- B. Europe
  - Market Analysis
  - Exhibit 152: RNAi (2005-2012) - European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Exhibit 153: List of Major Companies in Europe
  - Analysis by Application
  - Exhibit 154: RNAi (2005-2012) - European Market Analysis (Current & Future) by Application Area for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 155: RNAi (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Application Area for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 156: European Application Market Analysis (Current & Future) by Research for Genetics, Metabolism, Protein Chemistry & Others in US$ Million (Graphical Representation Included)
  - Exhibit 157: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 158: RNAi in Therapeutics (2005-2012) - European Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 159: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other
  - Application Analysis by Drug Development
  - Exhibit 160: RNAi in Drug Development (2005 - 2012)- European Market Analysis (Current & Future) for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 161: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of European Market Value for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 162: RNAi (2005-2012) - European Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 163: RNAi (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing , Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 164: RNAi Design/Software Tools/Products (2005-2012) - European Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 165: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 166: RNAi Synthesis Tools/Products (2005-2012) - European Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 167: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value for Expression Vector, Chemical, miRNA isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 168: RNAi Delivery Tools/Products (2005-2012) - European Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 169: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 170: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - European Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 171: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 172: RNAi Libraries Tools/Products (2005-2012) - European Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 173: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of European Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- B1. Germany
  - German Market Analysis
  - Exhibit 174: RNAi (2005-2012) - German Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 175: RNAi (2005-2012) - German Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 176: RNAi (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 177: RNAi in Research (2005-2012) - German Market Analysis (Current & Future) - by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 178: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Appliation for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 179: RNAi in Therapeutics (2005-2012) - German Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 180: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other
  - Application Analysis by Drug Development
  - Exhibit 181: RNAi in Drug Development (2005-2012)- German Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 182: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 183: RNAi (2005-2012) - German Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 184: RNAi (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other (Graphical Representation Included)
  - Tools/Products Analysis by Design/Software
  - Exhibit 185: RNAi Design/Software Tools/Products (2005-2012) - German Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 186: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of German Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other (Graphical Representation Included)
  - Tools/Products Analysis by Synthesis
  - Exhibit 187: RNAi Synthesis Tools/Products (2005-2012) - German Market Analysis (Current & Future) Synthesis for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 188: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of German Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 189: RNAi Delivery Tools/Products (2005-2012) - German Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 190: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of German Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 191: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - German Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 192: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of German Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products by Libraries
  - Exhibit 193: RNAi Libraries Tools/Products (2005-2012) - German Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 194: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of German Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- B2. The United Kingdom
  - UK Market Analysis
  - Exhibit 195: RNAi (2005-2012) - United Kingdom Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 196: RNAi (2005-2012) - United Kingdom Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 197: RNAi (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 198: RNAi in Research (2005-2012) - United Kingdom Market Analysis (Current & Future) by Application for Functional Genomics, Protein Chemistry Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 199: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 200: RNAi in Therapeutics (2005-2012)- United Kingdom Market Analysis (Current & Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 201: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other
  - Application Analysis by Drug Development
  - Exhibit 202: RNAi in Drug Development (2005-2012) - United Kingdom Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 203: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 204: RNAi (2005-2012) - United Kingdom Market Analysis (Current & Future) by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 205: RNAi (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other (Graphical Representation Included)
  - Tools/Products Analysis by Design/Software
  - Exhibit 206: RNAi Design/Software Tools/Products (2005-2012) - United Kingdom Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 207: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 208: RNAi Synthesis Tools/Products (2005-2012) - United Kingdom Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 209: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 210: RNAi Delivery Tools/Products (2005-2012) - United Kingdom Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 211: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 212: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - UK Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 213: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 214: RNAi Libraries Tools/Products (2005-2012) - United Kingdom Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 215: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- B3. Belgium
  - Belgian Market Analysis
  - Exhibit 216: RNAi (2005-2012) - Belgian Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 217: RNAi (2005-2012) - Belgian Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 218: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 219: RNAi in Research (2005-2012) - Belgian Market Analysis (Current and Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 220: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 221: RNAi in Therapeutics (2005-2012) - Belgian Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 222: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other
  - Application Analysis by Drug Development
  - Exhibit 223: RNAi in Drug Development (2005-2012) - Belgian Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 224: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 225: RNAi (2005-2012) - Belgian Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/ Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 226: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 227: RNAi Design/Software Tools/Products (2005-2012) - Belgian Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 228: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 229: RNAi Design/Software Tools/Products (2005-2012) - Belgian Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/ RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 230: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value Synthesis for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 231: RNAi Delivery Tools/Products (2005-2012) - Belgian Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 232: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 233: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Belgian Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 234: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 235: RNAi Libraries Tools/Products (2005-2012) Belgian Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 236: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- B4. France
  - French Market Analysis
  - Exhibit 237: RNAi (2005-2012) - French Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 238: RNAi (2005-2012) - French Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 239: RNAi (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 240: RNAi in Research (2005-2012) - French Market Analysis (Current & Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 241: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 242: RNAi in Therapeutics (2005-2012) - French Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 243: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other
  - Application Analysis by Drug Development
  - Exhibit 244: RNAi in Drug Development (2005-2012) - French Market Analysis (Current & Future) - by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 245: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 246: RNAi (2005-2012) - French Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 247: RNAi (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 248: RNAi Design/Software Tools/Products (2005-2012) - French Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 249: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of French Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 250: RNAi Synthesis Tools/Products (2005-2012) - French Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 251: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of French Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 252: RNAi Delivery Tools/Products (2005-2012) - French Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 253: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of French Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 254: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - French Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 255: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of French Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 256: RNAi Libraries Tools/Products (2005-2012) - French Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 257: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of French Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- B5. Rest of Europe
  - Rest of Europe Market Analysis
  - Exhibit 258: RNAi (2005-2012) - Rest of Europe Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 259: RNAi (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 260: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 261: RNAi in Research (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 262: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 263: RNAi in Therapeutics (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 264: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other
  - Application Analysis by Drug Development
  - Exhibit 265: RNAi in Drug Development (2005-2012) - Rest of Europe Market Analysis (Current & Future) for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 266: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 267: RNAi (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 268: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 269: RNAi Design/Software Tools/Products (2005-2012) - Rest of Europe Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 270: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 271: RNAi Synthesis Tools/Products (2005-2012) - Rest of Europe Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 272: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value for Expression Vectors, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 273: RNAi Delivery Tools/Products (2005-2012) - Rest of Europe Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 274: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 275: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Rest of Europe Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 276: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 277: RNAi Libraries Tools/Products (2005-2012) - Rest of Europe Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 278: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- C. Asia-Pacific
  - Asia-Pacific Market Analysis
  - Exhibit 279: RNAi (2005-2012) - Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Exhibit 280: List of Major Companies in Asia-Pacific
  - Analysis by Application
  - Exhibit 281: RNAi (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 282: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 283: RNAi in Research (2005-2012) - Asia-Pacific Market Analysis (Current and Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 284: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 285: RNAi in Therapeutics (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 286: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
  - Application Analysis by Drug Development
  - Exhibit 287: RNAi in Drug Development (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 288: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 289: RNAi (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 290: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 291: RNAi Design/Software Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 292: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 293: RNAi Synthesis Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 294: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other (Graphical Representation Included)
  - Tools/Products Analysis by Delivery
  - Exhibit 295: RNAi Delivery Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation, and Other in US$ Million (Graphical Representation Included)
  - Exhibit 296: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 297: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 298: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 299: RNAi Libraries Tools/Products (2005-2012) - Asia-Pacific Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 300: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- C1. Australia
  - Australian Market Analysis
  - Exhibit 301: RNAi (2005-2012) - Australian Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 302: RNAi (2005-2012) - Australian Market Analysis (Current & Future) - by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 303: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 304: RNAi in Research (2005-2012) - Australian Market Analysis (Current and Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 305: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 306: RNAi in Therapeutics (2005-2012) - Australian Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 307: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
  - Application Analysis by Drug Development
  - Exhibit 308: RNAi in Drug Development (2005-2012) - Australian Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 309: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 310: RNAi (2005-2012) - Australian Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 311: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 312: RNAi Design/Software Tools/Products (2005-2012) - Australian Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 313: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 314: RNAi Synthesis Tools/Products (2005-2012) - Australian Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 315: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 316: RNAi Delivery Tools/Products (2005-2012) - Australian Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 317: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 318: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Australian Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 319: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 320: RNAi Libraries Tools/Products (2005-2012) - Australian Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 321: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- C2. Japan
  - Japanese Market Analysis
  - Exhibit 322: RNAi (2005-2012) - Japanese Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 323: RNAi (2005-2012) - Japanese Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 324: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 325: RNAi in Research (2005-2012) - Japanese Market Analysis (Current and Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 326: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 327: RNAi in Therapeutics (2005-2012) - Japanese Market Analysis (Current and Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 328: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
  - Application Analysis by Drug Development
  - Exhibit 329: RNAi in Drug Development (2005-2012) - Japanese Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 330: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other (Graphical Representation Included)
  - Analysis by Tools/Products
  - Exhibit 331: RNAi (2005-2012) - Japanese Market Analysis (Current & Future) by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 332: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Tools/ Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing , Libraries and Other (Graphical Representation Included)
  - Tools/Products Analysis by Design/Software
  - Exhibit 333: RNAi Design/Software Tools/Products (2005-2012) - Japanese Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 334: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 335: RNAi Synthesis Tools/Products (2005-2012) - Japanese Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 336: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 337: RNAi Delivery Design/Software Tools/Products (2005-2012) - Japanese Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 338: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value for Vector Based, Transfection Reagents, Electroporation and Other
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 339: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Japanese Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 340: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 341: RNAi Libraries Tools/Products (2005-2012) - Japanese Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 342: RNAi LibrariesTools/Products (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- C3. Rest of Asia-Pacific
  - Exhibit 343: RNAi (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 344: RNAi (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 345: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 346: RNAi in Research (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 347: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Application for Functional Genomics, Protein Chemistry, Metabolism and Other
  - Application Analysis by Therapeutics
  - Exhibit 348: RNAi in Therapeutics (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
  - Exhibit 349: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Application Market Value by Application for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
  - Application Analysis by Drug Development
  - Exhibit 350: RNAi in Drug Development (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 351: RNAi in Drug Development (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Application for Target Validation, Target Identification, Drug Mechanism and Other
  - Analysis by Tools/Products
  - Exhibit 352: RNAi (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
  - Exhibit 353: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Tools/Products for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
  - Tools/Products Analysis by Design/Software
  - Exhibit 354: RNAi Design/Software Tools/Products (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
  - Exhibit 355: RNAi Design/Software Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value for miRNA Target Scan, miRNA Analysis Software, Design Algorithm and Other
  - Tools/Products Analysis by Synthesis
  - Exhibit 356: RNAi Synthesis Tools/Products (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
  - Exhibit 357: RNAi Synthesis Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value for Expression Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
  - Tools/Products Analysis by Delivery
  - Exhibit 358: RNAi Delivery Tools/Products (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) for Vector Based, Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
  - Exhibit 359: RNAi Delivery Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value for Vector Based, Transfection Reagents, Electroporation and Other (Graphical Representation Included)
  - Tools/Products Analysis by Monitoring/Optimizing
  - Exhibit 360: RNAi Monitoring/Optimizing Tools/Products (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) for Primers for RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
  - Exhibit 361: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value for Primers for RTqPCR, Controls, miRNA Detection Tools and Other
  - Tools/Products Analysis by Libraries
  - Exhibit 362: RNAi Libraries Tools/Products (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million (Graphical Representation Included)
  - Exhibit 363: RNAi Libraries Tools/Products (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value for Human, Mouse, Rat and Other (Graphical Representation Included)
- D. Rest of World
  - Rest of World Market Analysis
  - Exhibit 364: RNAi (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Analysis by Application
  - Exhibit 365: RNAi (2005-2012) - Rest of World Market Analysis (Current & Future) by Application for Research, Therapeutics, Drug Development and Other in US$ Million (Graphical Representation Included)
  - Exhibit 366: RNAi (2006, 2009 and 2012) - Percentage Breakdown of Rest of World Market Value by Application for Research, Therapeutics, Drug Development and Other (Graphical Representation Included)
  - Application Analysis by Research
  - Exhibit 367: RNAi in Research (2005-2012) - Rest of World Market Analysis (Current and Future) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
  - Exhibit 368: RNAi in Research (2006, 2009 and 2012) - Percentage Breakdown of Rest of World Market Value by Application for Functional

RNAi：市場動向調査報告